{"product_id":"mygn-bcg-matrix","title":"(MYGN) Myriad Genetics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Myriad Genetics, Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. What you see on this page is a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneSight Psychotropic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneSight Psychotropic is Myriad Genetics' flagship mental-health pharmacogenomic test, and it still leads a psychotropic market that is expanding as providers try to cut trial-and-error prescribing. By late 2025, its broad brand reach and growing use support a Star profile: strong market share in a category with rising demand. It is the clearest growth engine in Myriad Genetics' portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyChoice CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyChoice CDx is Myriad Genetics, Inc.'s tumor-based HRD test for ovarian cancer treatment selection, and it fits a growing companion-diagnostic niche tied to PARP inhibitors. Roughly 50% of high-grade serous ovarian cancers show homologous recombination deficiency, which keeps demand for this assay meaningful. Myriad Genetics, Inc. has a strong clinical foothold here, so MyChoice CDx supports Star status in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrequel Prenatal Screen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrequel Prenatal Screen is Myriad Genetics, Inc.'s non-invasive prenatal screening test that uses maternal blood, and it fits a high-growth niche as prenatal testing volumes rise and panels widen. In FY2025, Myriad Genetics kept prenatal genetics in focus while the U.S. still saw about 3.6 million births a year, supporting a large addressable market. If Prequel keeps taking share, it has Star status in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eForesight Carrier Screen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eForesight Carrier Screen fits the Star bucket because it serves carrier screening in reproductive health, where preconception and prenatal testing demand keeps broadening. If Myriad Genetics, Inc. holds strong share as the market expands, the franchise can keep scaling with it.\u003c\/p\u003e\n\u003cp\u003eIn Myriad Genetics, Inc.'s 2025 to 2026 mix, this is the kind of asset that can support growth if volume rises faster than pricing pressure. One line: growth in reproductive testing is the key.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCarrier screening demand is expanding\u003c\/li\u003e\n\u003cli\u003ePreconception and prenatal use cases grow\u003c\/li\u003e\n\u003cli\u003eStar status depends on sustained share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrecise Tumor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrecise Tumor fits Myriad Genetics, Inc.’s broader personalized oncology push, and precision oncology is still a fast-growing diagnostics niche. Myriad reported FY2025 revenue of about $840 million, with oncology assets central to its growth plan, which supports the Star case. The category keeps expanding as more cancers are matched to biomarker-driven testing and treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth oncology diagnostics\u003c\/li\u003e\n\u003cli\u003eBacked by Myriad FY2025 investment\u003c\/li\u003e\n\u003cli\u003eStar potential, but execution matters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Star Tests Still Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. stars are GeneSight, MyChoice CDx, Prequel, and Foresight, because each sits in a growing test market and still holds clear share. FY2025 revenue was about $840 million, so these franchises matter to the top line. One line: growth still comes from volume, not price.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight\u003c\/td\u003e\n\u003ctd\u003eMental-health PGx leader\u003c\/td\u003e\n\u003ctd\u003eFlagship growth driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrequel\u003c\/td\u003e\n\u003ctd\u003ePrenatal testing growth\u003c\/td\u003e\n\u003ctd\u003eU.S. births ~3.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyChoice CDx\u003c\/td\u003e\n\u003ctd\u003eHRD oncology niche\u003c\/td\u003e\n\u003ctd\u003e~50% HGSOC HRD rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMyriad Genetics BCG Matrix: quadrant-by-quadrant view of growth, cash, and divestment priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot for Myriad Genetics, Inc. to spot growth, cash, and drag at a glance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Myriad Genetics data, boosting credibility and speeding investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyRisk Hereditary Cancer Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyRisk Hereditary Cancer Test is one of Myriad Genetics, Inc.'s core hereditary cancer panels, and it sits in a more mature market than newer oncology or prenatal lines. Its strong brand and installed base help it act as a cash generator for the portfolio.\u003c\/p\u003e\n\u003cp\u003eIn FY2025, Myriad Genetics, Inc. still leaned on hereditary cancer testing as a key revenue driver, even as it pushed newer products. That steadier demand makes MyRisk less of a growth story and more of a funding engine.\u003c\/p\u003e\n\u003cp\u003eFor a BCG Matrix view, MyRisk fits the Cash Cow box: high share in a slow-growing category, with recurring test demand and proven clinical use supporting margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBRACAnalysis CDx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBRACAnalysis CDx is Myriad Genetics' FDA-cleared companion diagnostic for BRCA1\/2 variants, tied to PARP inhibitor and other oncology decisions. It sits in a mature testing lane, so growth is modest, but the 2-gene franchise still throws off steady cash because it is embedded in routine hereditary cancer workflows and remains clinically relevant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProlaris Prostate Cancer Prognostic Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProlaris is a clinically established prostate cancer prognostic test, and that fits a cash cow profile in Myriad Genetics, Inc.’s BCG mix. The U.S. still expects about 313,780 new prostate cancer cases in 2025, but the risk-testing space is mature, so growth is steadier than explosive. That means Prolaris can keep generating cash through an entrenched clinical role, even if it is not the main growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEndoPredict Breast Cancer Prognostic Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEndoPredict Breast Cancer Prognostic Test fits the Cash Cows bucket because it is a mature, clinically established assay that helps Myriad Genetics, Inc. generate steady revenue rather than chase fast new growth. In a proven breast cancer prognostic market, demand is tied to routine treatment decisions, so cash flow is more stable than in newer precision-oncology products.\u003c\/p\u003e\n\u003cp\u003eMyriad Genetics, Inc. uses EndoPredict to defend share in a well-known category, where payor coverage and clinician adoption matter more than breakout expansion. The test’s role is clear: support recurring sales and margin discipline, not a heavy reinvestment cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable, mature breast cancer assay\u003c\/li\u003e\n\u003cli\u003eSupports recurring cash flow\u003c\/li\u003e\n\u003cli\u003eLower growth, lower reinvestment need\u003c\/li\u003e\n\u003cli\u003eFits Cash Cows in BCG Matrix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHereditary Cancer Reporting Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc.'s hereditary cancer reporting base is a cash cow because the interpretation and reporting system already supports a mature menu, including MyRisk with 48 genes and BRACAnalysis. The clinical installed base is deep, so new reports add revenue with limited launch cost. In FY2024, Myriad generated about $800 million in revenue, and this base helps defend that recurring stream.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e48-gene hereditary cancer menu\u003c\/li\u003e\n\u003cli\u003eMature installed clinical base\u003c\/li\u003e\n\u003cli\u003eLow incremental launch cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Cash Cows Keep Revenue Steady in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc.'s Cash Cows are the mature hereditary cancer assets, led by MyRisk and BRACAnalysis CDx. In FY2025, hereditary cancer testing still anchored revenue while newer lines grew slower, so these products acted as steady cash generators, not growth drivers. Their value comes from entrenched clinical use, repeat demand, and low reinvestment needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMyRisk\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eCore hereditary cancer revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRACAnalysis CDx\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003ctd\u003eStable companion diagnostic demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eMyriad Genetics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Myriad Genetics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages or placeholder content—just the full, ready-to-use file. It’s formatted for clear strategic analysis and immediate professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Single-Gene BRCA Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy Single-Gene BRCA Testing is a Dog for Myriad Genetics, Inc.: it covers just 2 genes, while MyRisk panels cover up to 48 genes, so demand keeps shifting to broader hereditary cancer testing. That leaves BRCA-only volume with low growth and low strategic value. The category is now more of a tail product than a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Custom Molecular Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLow-volume custom molecular testing sits in the \"Dogs\" box because it is not a scale driver and usually lacks clear differentiation. In FY2025, Myriad Genetics generated about $0.84B in revenue, so small one-off work can still tie up high-value lab capacity without moving the needle much. If these services do not earn premium margins or repeat volume, they can turn into a cash trap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall Non-Core International Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. still earns most of its value from core U.S. brands, while small non-core international services stay niche and face tougher reimbursement and lower share. That mix fits the Dog bucket: weak relative position, limited scale, and little pricing power. Unless Myriad can lift reimbursement or expand volume, these businesses are likely cash traps, not growth engines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMature Standalone Add-On Panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics, Inc.'s mature standalone add-on panels fit the Dogs box: small panels are easy to copy, and larger rivals can bundle broader menus at lower cost. In a low-growth market, Myriad Genetics, Inc. also lacks the share needed to win on price or scale, so these panels tend to trap capital with weak upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall panels commoditize fast\u003c\/li\u003e\n\u003cli\u003eBig rivals bundle cheaper\u003c\/li\u003e\n\u003cli\u003eLow growth, low share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiscontinued Legacy Assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiscontinued legacy assays sit in the Dogs box because they no longer drive growth and now live mostly as a small installed-base tail. Myriad Genetics, Inc. has shifted capital toward newer, higher-demand tests, so these older assays add little to 2026 revenue momentum and usually carry only limited renewal volume.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low strategic priority\u003c\/li\u003e\n\u003cli\u003eMostly installed-base revenue\u003c\/li\u003e\n\u003cli\u003eCapital moves to newer assays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTail Products Weigh on Myriad’s Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at Myriad Genetics, Inc. are legacy BRCA-only, small add-on, and low-volume custom assays: they have weak growth, low share, and little pricing power. FY2025 revenue was about $0.84B, but these tail products do not drive the mix shift toward higher-value panels. They mostly use capacity without adding much scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog segment\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLegacy BRCA-only\u003c\/td\u003e\n\u003ctd\u003e2 genes vs up to 48\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecise Tumor Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics, Inc. launched Precise Tumor after its core hereditary and prenatal franchises, so it is still a newer, smaller 2025 growth driver. The tumor-profiling market is still expanding, but it is crowded, with heavy competition from Foundation Medicine and Guardant Health. Precise Tumor needs clear share gains and faster adoption to move out of Question Mark status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntermountain Precision Genomics Alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntermountain Precision Genomics Alliance helps Myriad Genetics expand germline and somatic tumor testing inside a care network that faces about 2.0 million new U.S. cancer cases in 2025. That gives Myriad a faster path into oncology workflows, but the alliance is still a Question Mark until it proves real share and repeat test volume.\u003c\/p\u003e\n\u003cp\u003ePartnership-led access can speed adoption, yet Myriad still has to convert that reach into durable revenue and margin gain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanded Somatic Tumor Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExpanded somatic tumor testing sits in a fast-growing space, since solid tumors account for roughly 90% of cancer cases. Myriad Genetics, Inc. has room to win share, but the market is crowded with large labs and specialty rivals, so growth will likely need heavier spend on assay breadth, reimbursement, and sales reach. It can become a Star only if that investment lifts volume faster than rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew Prenatal Add-Ons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew Prenatal Add-Ons fit the Question Mark spot: prenatal genetics keeps adding markers and workflow steps, but Myriad Genetics, Inc. still needs payer wins and clinician uptake to scale share. In BCG terms, the category has growth potential, yet demand can stay uneven until coverage becomes routine. The key test is whether add-on tests move from niche use to standard prenatal panels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low share today\u003c\/li\u003e\n\u003cli\u003ePayer coverage is the swing factor\u003c\/li\u003e\n\u003cli\u003eAdoption speed decides future share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational Rollouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutside the U.S., Myriad Genetics, Inc. faces local rivals and patchy reimbursement, so rollout speed stays uneven. That keeps International Rollouts in Question Mark territory: the addressable market in oncology and reproductive health is real, but current share is still low. The next step is proving payer access country by country.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal competitors दब crowd the market.\u003c\/li\u003e\n\u003cli\u003eReimbursement varies by country.\u003c\/li\u003e\n\u003cli\u003eOncology and reproductive health still offer upside.\u003c\/li\u003e\n\u003cli\u003eLow share keeps returns uncertain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad’s Question Marks: High Growth, Low Share, 2025 Will Decide\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks at Myriad Genetics, Inc. are newer oncology and prenatal bets with high growth but low share. Precise Tumor, Intermountain Precision Genomics Alliance, and international rollouts can grow fast, but 2025 adoption, payer access, and repeat volume still decide if they scale or stay niche.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrecise Tumor\u003c\/td\u003e\n\u003ctd\u003eCrowded market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology access\u003c\/td\u003e\n\u003ctd\u003eAbout 2.0M U.S. cancer cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234716918025,"sku":"mygn-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mygn-bcg-matrix.webp?v=1785725812","url":"https:\/\/dcfanalyst.com\/products\/mygn-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}